Contamination Measurements of Patient’s Lead-Insulated Rooms After I-131 and LU-177 PSMA Treatment via Sweeping Test
Abstract
I-131 and Lu-177 PSMA radionuclides have been widely used in the field of nuclear medicine to treat thyroid cancer for many years. In this treatment, the patients whose dose rate measurements are less than 3 mR/h are generally discharged from the lead-insulated rooms where they are hospitalized. The aim of our study is to evaluate the contamination measurements of these rooms after I-131 and LU-177 PSMA treatment and to ensure radiation safety. A sweeping test was carried out by using Whatman papers (10x10 cm2 in size) to take samples from designated areas of these rooms in which three patients were treated with Lu-177 PSMA and four patients were treated with the I-131 radionuclide. Whatman papers are placed inside different tubes to prevent external contamination. Afterward, counting procedure was taken to the tubes for one minute by using the gamma counter which has different calibration factors both for Lu-177 and I-131 radionuclides. For the background extraction, one-minute counting test was applied to one of the Whatman papers that were not used for sweeping and background value was then obtained. It was statistically understood that the highest contamination rate was observed on the surface of toilet potteries in each room. As a result, ventilation of the room, meticulous cleaning of contaminated areas and the sweeping test must be implemented in each room where the patients are treated with radionuclides before the treatment of other patients.
Keywords
References
- [1]. Ahmadzadehfar H., Eppard E., Kurpig S., Fimmers R., Yordanova A., Schlenkhoff C.D., Gartner F., Rogenhofer S. and Essler M., Therapeutic Response and Side Effects of Repeated Radioligand Therapy with 177 Lu-PSMA-DKFZ-617 of Castrate-Resistant Metastatic Prostate Cancer, Oncotarget 7 (2016) 12477-12488.
- [2]. Rahbar K., Schmidt M., Heinzel A., Eppard E., Bode A., Yordanova A., Claesener M. and Ahmadzadehfar H., Response and Tolerability of a Single Dose of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: a Multicenter Retrospective Analysis, J. Nucl. Med. 57 (2016) 1334–1339.
- [3]. Yeyin N., Akyel R., Abuqbeitah M., Çavdar İ., Sönmezoğlu K. and Demir M., The Evaluation of Dose Rate Measurements and Discharge Time After Radionuclide Therapy, J Ist Faculty Med 80 (2017) 1-6.
- [4]. Daniels G. H., Radioactive Iodine: A Slice of History, Thyroid 23 (2013) 253-258.
- [5]. Demir M., Radiobiological Effects, Protection of the Patient, Protection of Caregivers, Protection of Those Around the Patient and the Environment, Nuclear Medicine Seminars 1 (2015) 3171-3190.
- [6]. Casara D., Rubello D., Saladini G., Piotto A., Peiizzo M.R., Girelli M.E., Busnardo B., Pregnancy After High Therapeutic Doses of Iodine-131 in Differentiated Thyroid Cancer: Potential Risks and Recommendations, Eur J Nucl Med Mol Imaging 20 (1993) 192–194.
- [7]. Lakshmanan M., Schaffer A., Robbins J., Reynolds J. and Norton J., A Simplified Low Iodine Diet in I-131 Scanning and Therapy of Thyroid Cancer, Clin Nucl Med 13(1988) 866-880.
- [8]. Demir M., Nükleer Tıp Fiziği ve Klinik Uygulamaları, 3rd ed. Turkey, Chap 2.
Details
Primary Language
English
Subjects
-
Journal Section
Conference Paper
Authors
Tuğba Demirbay
*
Yıldız Technical University, Faculty of Science & Letters, Physics Department
Türkiye
Kübra Harman
*
Sinop University, Faculty of Engineering and Architecture, Nuclear Energy Engineering
Türkiye
Mustafa Demir
İstanbul University, Cerrahpaşa Medical School, Nuclear Medicine Department
Türkiye
Publication Date
June 29, 2018
Submission Date
November 30, 2017
Acceptance Date
April 5, 2018
Published in Issue
Year 2018 Volume: 39 Number: 2